Document Detail

Effects of selective phosphodiesterase-5-inhibition on myocardial contractility and reperfusion injury after heart transplantation.
MedLine Citation:
PMID:  19034012     Owner:  NLM     Status:  MEDLINE    
Recently, the infarct reducing and cardioprotective effects of phosphodiesterase-5-inhibitors were described. In this study, we investigated these effects on ischemia/reperfusion injury in a rat model of heart transplantation. Three groups were assigned for our study: a vardenafil preconditioning group, an ischemic control, and a nonischemic control. Hemodynamic parameters were significantly increased in the vardenafil group (Pmax: 82+/-4 vs. 110+/-12 vs. 127+/-13 mm Hg; dP/dtmax: 1740+/-116 vs. 3197+/-599 vs. 4397+/-602 mm Hg/sec; ischemic control vs. vardenafil vs. nonischemic control; P<0.05 vs. ischemic control). Furthermore, we recorded increased ATP levels and significantly less apoptosis in the treatment group after terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (apoptosis index: 27.23%+/-1.54% vs. 16.77%+/-1.42% vs. 18.86%+/-1.07%; ischemic control vs. vardenafil vs. nonischemic control; P<0.05 vs. ischemic control). Our current results support the concept that the cGMP-PKG-pathway plays an important role in ischemia/reperfusion injury. We could show that up-regulating this pathway has a preconditioning-like effect and can effectively reduce ischemia/reperfusion injury.
Sivakkanan Loganathan; Tamás Radovits; Kristóf Hirschberg; Sevil Korkmaz; Eniko Barnucz; Matthias Karck; Gábor Szabó
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation     Volume:  86     ISSN:  1534-6080     ISO Abbreviation:  Transplantation     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-26     Completed Date:  2008-12-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1414-8     Citation Subset:  IM    
Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aorta, Abdominal / surgery
Cyclic GMP / metabolism
Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism*
Heart Transplantation / physiology*
Hemodynamics / drug effects*
Imidazoles / therapeutic use*
Myocardial Contraction / drug effects*
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use*
Postoperative Complications / prevention & control*
Rats, Inbred Lew
Reperfusion Injury / prevention & control*
Sulfones / therapeutic use
Systole / drug effects
Transplantation, Heterotopic
Transplantation, Isogeneic
Triazines / therapeutic use
Vena Cava, Inferior / surgery
Ventricular Function, Left / drug effects,  physiology
Reg. No./Substance:
0/Imidazoles; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Sulfones; 0/Triazines; 224785-90-4/vardenafil; 7665-99-8/Cyclic GMP; EC Nucleotide Phosphodiesterases, Type 5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte- a...
Next Document:  Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of hum...